Journal
TRENDS IN IMMUNOLOGY
Volume 36, Issue 4, Pages 265-276Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2015.02.008
Keywords
PD-1; PD-L1; T cell exhaustion; immunotherapy; cancer; chronic infection
Categories
Funding
- National Institutes of Health [AI082630, AI05343, AI112521]
- Robertson Foundation/Cancer Research Institute Irvington Fellowship
Ask authors/readers for more resources
Inhibitors of the Programmed Cell Death 1: Programmed Cell Death 1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell exhaustion, have been recently shown to be effective for treatment of different cancers. However, clinical responses are mixed, highlighting the need to better understand the mechanisms of action of PD1:PD-L1, the role of this pathway in immunity to different tumors, and the molecular and cellular effects of PD-1 blockade. Here, we review the molecular regulation of T cell exhaustion, placing recent findings on PD-1 blockade therapies in cancer in the context of the broader understanding of the roles of the PD-1:PD-L1 pathway in T cell exhaustion during chronic infection. We discuss the current understanding of the mechanisms involved in reversing T cell exhaustion, and outline critical areas of focus for future research, both basic and clinical.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available